Meinian Onehealth(002044) 东吴证券·2024-11-08 05:56Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a significant improvement in profitability in Q3 2024, with a year-on-year increase in net profit of 10.3% and a gross profit margin of 45.43% [2][3] - The company is focusing on an "innovation-driven" development strategy, launching specialized health examination projects and AI-driven health management products, including the "Health Xiaomei" AI robot [3] - The number of branches continues to expand, with a total of 608 branches as of September 30, 2024, maintaining a leading position in the industry in terms of coverage and examination volume [3] Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 7.141 billion yuan, a decrease of 1.96% year-on-year, and a net profit of 25 million yuan, down 88.96% [2] - In Q3 2024 alone, the company reported a revenue of 2.935 billion yuan, an increase of 3.63% year-on-year, and a net profit of 240 million yuan, up 10.33% [2] - The company's revenue forecast for 2024-2026 has been adjusted, with expected net profits of 400 million yuan, 703 million yuan, and 999 million yuan for the respective years [3]